Search

Your search keyword '"Mikaela Odemyr"' showing total 19 results
Start Over Author "Mikaela Odemyr"
19 results on '"Mikaela Odemyr"'

1. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Author

Torsten Zuberbier, Amir Abdul Latiff, Xenofon Aggelidis, Matthias Augustin, Radu‐Gheorghe Balan, Christine Bangert, Lisa Beck, Thomas Bieber, Jonathan A. Bernstein, Marta Bertolin Colilla, Alejandro Berardi, Anna Bedbrook, Carsten Bindslev‐Jensen, Jean Bousquet, Marjolein deBruin‐Weller, Dayanne Bruscky, Betul Buyuktiryaki, Giorgio Walter Canonica, Carla Castro, Natia Chanturidze, Herberto Jose Chong‐Neto, Chia‐Yu Chu, Leena Chularojanamontri, Michael Cork, Roberta F. J. Criado, Laia Curto Barredo, Adnan Custovic, Ulf Darsow, Arben Emurlai, Ana dePablo, Stefano DelGiacco, Giampiero Girolomoni, Tanja Deleva Jovanova, Mette Deleuran, Nikolaos Douladiris, Bruno Duarte, Ruta Dubakiene, Esben Eller, Batya Engel‐Yeger, Luis Felipe Ensina, Nelson Rosario Filho, Carsten Flohr, Daria Fomina, Wojciech Francuzik, Maria Laura Galimberti, Ana M. Giménez‐Arnau, Kiran Godse, Charlotte Gotthard Mortz, Maia Gotua, Michihiro Hide, Wolfram Hoetzenecker, Nicolas Hunzelmann, Alan Irvine, Carolyn Jack, Ioanna Kanavarou, Norito Katoh, Tamar Kinaciyan, Emek Kocatürk, Kanokvalai Kulthanan, Hilde Lapeere, Susanne Lau, Mariana Machado Forti Nastri, Michael Makris, Eli Mansour, Alexander Marsland, Mara Morelo Rocha Felix, Ana Paula Moschione Castro, Eustachio Nettis, J. F. Nicolas, Audrey Nosbaum, Mikaela Odemyr, Niki Papapostolou, Claudio A. S. Parisi, Sushil Paudel, Jonny Peter, Prakash Pokharel, Luis Puig, Tamara Quint, German Dario Ramon, Frederico Regateiro, Giampaolo Ricci, Cristine Rosario, Cansin Sackesen, Peter Schmid‐Grendelmeier, Esther Serra‐Baldrich, Kristina Siemens, Cathrine Smith, Petra Staubach, Katarina Stevanovic, Özlem Su‐Kücük, Gordon Sussman, Simona Tavecchio, Natasa Teovska Mitrevska, Diamant Thaci, Elias Toubi, Claudia Traidl‐Hoffmann, Regina Treudler, Zahava Vadasz, Ingrid vanHofman, Maria Teresa Ventura, Zhao Wang, Thomas Werfel, Andreas Wollenberg, Ariana Yang, Yik Weng Yew, Zuotao Zhao, Ricardo Zwiener, and Margitta Worm

Subjects
atopic dermatitis, eczema, guidance, ICP, integrated care pathways, multidisciplinary, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Introduction The integrated care pathways for atopic dermatitis (AD‐ICPs) aim to bridge the gap between existing AD treatment evidence‐based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co‐ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems. Methods The GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD‐ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres. Results The AD‐ICPs outline the diagnostic procedures, possible co‐morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD. Conclusion The AD‐ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.

Published
2023
Full Text
View/download PDF

2. Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union's new recommendations on lung cancer screening

Author

Brian Ward, Martina Koziar Vašáková, Carlos Robalo Cordeiro, Arzu Yorgancioğlu, Joanna Chorostowska-Wynimko, Torsten Gerriet Blum, Hans-Ulrich Kauczor, Miroslav Samarzija, Claudia Henschke, Craig Wheelock, Jonathan Grigg, Zorana Jovanovic Andersen, Vladimír Koblížek, Ondřej Májek, Mikaela Odemyr, Pippa Powell, and Luis M. Seijo

Subjects
Medicine
Published
2023
Full Text
View/download PDF

3. Patient's treatment burden related to care coordination in the field of respiratory diseases

Author

Paola Pierucci, Carla Santomasi, Nicolino Ambrosino, Andrea Portacci, Fabrizio Diaferia, Kjeld Hansen, Mikaela Odemyr, Steve Jones, and Giovanna E. Carpagnano

Subjects
Diseases of the respiratory system, RC705-779
Abstract

The management of respiratory diseases requires various levels of care: multidisciplinary teams, educational and behavioural interventions, self-management and home-based technical support are vital to ensure adequate care management. However, it is often difficult to access these networks due to fragmentation of patient care and treatment burden. Care coordination aims to ensure patients have a central role and that there is continuity of care among various levels and professionals involved. Moreover, the coronavirus disease pandemic has caused strain on the global healthcare system, with care coordination becoming increasingly important in increasing the resilience of health systems, supporting healthcare professionals and ensuring the right treatment and adequate level of care for these patients.

Published
2021
Full Text
View/download PDF

4. Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma

Author

Paraskevi Katsaounou, Mikaela Odemyr, Otto Spranger, Michael E. Hyland, Claus Kroegel, Lorena Garcia Conde, Robin Gore, Francesco Menzella, Christian Domingo Ribas, Mario Morais-Almeida, Matthias Gasser, and Ismail Kasujee

Subjects
Medicine
Abstract

We conducted a large global survey, Still Fighting for Breath, in patients with severe persistent asthma, 10 years after the Fighting for Breath survey to assess the impact of disease on patients' lives and to determine if control and management have changed in recent years. Data were collected from 1333 adults (aged >18 years) and caregivers of children (aged 6–17 years) with severe persistent asthma from nine countries through an online survey conducted in 2016 by GfK. A decade after the first survey, our results showed that the impact of severe asthma has not changed significantly and a high proportion of patients with severe asthma remain inadequately controlled. A large discrepancy was observed between the proportion of patients who perceived their asthma to be well controlled (42%) and the proportion of patients who reported to be well controlled as per the Global Initiative for Asthma (GINA) assessment (6%). Although most patients perceived their asthma to be controlled, many experienced frequent symptoms that affected their daily lives. Thus, there is a need for improved management (support and strategies) of patients with severe persistent asthma and improved coordination of efforts that would enable these patients to achieve better disease control.

Published
2018
Full Text
View/download PDF

5. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author

Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology

Subjects
Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion

Published
2021
Full Text
View/download PDF

6. Social and ethical factors in anaphylaxis

Author

Leyla Pur Ozyigit, Mikaela Odemyr, Elena Bradatan, Caroline Brall, Rouven Porz, and Glenis K. Scadding

Subjects
Immunology, Immunology and Allergy, Humans, Anaphylaxis
Published
2022

7. Smoking asthmatics, a neglected large phenotype of asthmatic patients

Author

Paraskevi Katsaounou, Lorena Garcia Conde, Matthias Gasser, Marios Ioannou, Mikaela Odemyr, Anne Lindberg, Michael E. Hyland, O. Spranger, Xavier Jaumont, and Ismail Kasujee

Subjects
medicine.medical_specialty, business.industry, Severe asthma, Severe persistent asthma, medicine.disease, respiratory tract diseases, Quality of life, immune system diseases, Asthma control, Internal medicine, medicine, Asthmatic patient, In patient, business, Asthma
Abstract

Introduction: Smoking in asthma patients is an important factor contributing to worsened control of asthma. Despite increased awareness of the harmful effects of smoking in patients with asthma, a significant proportion of asthmatics remain smokers. Here, we present findings from the Still Fighting for Breath global survey regarding the prevalence of smoking in patients with severe asthma, impact of smoking on asthma control and correlation of smoking with different aspects of quality of life in patients with severe persistent asthma.

Published
2019
Full Text
View/download PDF

8. Erklärung von Vilnius zu chronischen Atemwegserkrankungen: multisektorale Versorgungswege, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung chronischer Atemwegserkrankungen einschließen

Author

Sergey Sargsyan, Svetlana Cebatori, Brigita Sitkauskiene, David Somekh, Wytske Fokkens, Algirdas Utkus, Roberta Savli, Michael Bewick, Davit Sergeenko, Ioana Agache, Algirdas Valiulis, Anna Bedbrook, Joanna Chorostowska-Wynimko, Violeta Kvedariene, Edvardas Danila, S. Pietikainen, Jonathan Grigg, Danielle Borelli, Ulana Suprun, Peter Hellings, Adamos Hadjipanayis, Andrew Bush, Valentina Vilc, Tomas Alasevicius, Rusudan Karseladze, Laimute Vaideliene, Jean Bousquet, Nils Billo, Arunas Valiulis, Aurelijus Veryga, Bolesław Samoliński, Kaja Julge, Joanna Banys, Lokesh Dubey, Susana Palkonen, Mikaela Odemyr, Lars Münter, Tari Haahtela, Nikolai Khaltaev, Eugenijus Lesinskas, Ivane Chkaidze, and Oleksander Katilov

Abstract

Hintergrund: Mehr als eine Milliarde Menschen leiden an chronischen Atemwegserkrankungen wie Asthma, COPD, Rhinitis und Rhinosinusitis. Diese verursachen enorme Belastungen und gelten als schwerwiegende nicht übertragbare Erkrankungen. Viele Patienten sind noch unbehandelt und die Kosten der Untätigkeit sind nicht akzeptabel. Am 23. März 2018 fand in Vilnius eine Konferenz unter der Schirmherrschaft des Gesundheitsministeriums und verschiedener wissenschaftlicher Fachgesellschaften statt, auf der multisektorale Versorgungswege vorgeschlagen wurden, die angeleitetes Selbstmanagement, mHealth und Luftverschmutzung bei der Versorgung bestimmter chronischer Atemwegserkrankungen (Rhinitis, chronische Rhinosinusitis, Asthma und COPD) einschließen. Das Treffen schloss mit der Erklärung von Vilnius, die von den Teilnehmern des EU-Gipfels zu chronischen Atemwegserkrankungen unter der Federführung von Euforea entwickelt wurde. Schlussfolgerung: Die Erklärung von Vilnius ist ein wichtiger Schritt im Kampf gegen die weltweite Luftverschmutzung und ihre Auswirkungen für Patienten mit chronischen Atemwegserkrankungen und sie spielt im Hinblick auf die EU-Gesundheitsstrategie eine wichtige Rolle, da sie einen Zusatznutzen zu dem bereits vorhandenen Wissen über die öffentliche Gesundheit liefert.

Published
2019
Full Text
View/download PDF

9. Patient's treatment burden related to care coordination in the field of respiratory diseases

Author

Kjeld S. Hansen, Steve Jones, Giovanna Elisiana Carpagnano, Fabrizio Diaferia, Carla Santomasi, Mikaela Odemyr, Andrea Portacci, Paola Pierucci, and Nicolino Ambrosino

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, RC705-779, business.industry, media_common.quotation_subject, Treatment burden, MEDLINE, Reviews, Disease, Technical support, Diseases of the respiratory system, Multidisciplinary approach, Pandemic, medicine, Psychological resilience, Level of care, Intensive care medicine, business, media_common
Abstract

The management of respiratory diseases requires various levels of care: multidisciplinary teams, educational and behavioural interventions, self-management and home-based technical support are vital to ensure adequate care management. However, it is often difficult to access these networks due to fragmentation of patient care and treatment burden. Care coordination aims to ensure patients have a central role and that there is continuity of care among various levels and professionals involved. Moreover, the coronavirus disease pandemic has caused strain on the global healthcare system, with care coordination becoming increasingly important in increasing the resilience of health systems, supporting healthcare professionals and ensuring the right treatment and adequate level of care for these patients., Care coordination is fundamental in treating respiratory disease. Although it involves considerable effort it ensures professionals to work together to reduce the treatment burden for respiratory patients. https://bit.ly/2Qrrpz0

Published
2021

10. Correction to: Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases

Author

Joanna Chorostowska-Wynimko, V. Vilc, Sergey Sargsyan, Eugenijus Lesinskas, Tomas Alasevicius, U. Suprun, David Somekh, R. Savli, N. Khaltaev, P Hellings, Adamos Hadjipanayis, S. Pietikainen, S. Cebotari, S. Palkonen, Arunas Valiulis, Edvardas Danila, A. Bedbrook, Kaja Julge, Tari Haahtela, Jean Bousquet, D. Sergeenko, Lars Münter, Ioana Agache, Algirdas Valiulis, L. Vaideliene, M. Bewick, B. Sitkauskiene, L. Dubey, Violeta Kvedariene, Algirdas Utkus, I Chkhaidze, Aurelijus Veryga, Jonathan Grigg, W. J. Fokkens, O. Katilov, J. Banys, Andrew Bush, Mikaela Odemyr, Nils E. Billo, B. Samolinski, D. Borelli, and Rusudan Karseladze

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Self-management, Third party, business.industry, Public health, Immunology, University faculty, Declaration, Correction, Family medicine, Immunology and Allergy, Medicine, business, mHealth
Abstract

Following publication of the original article [1], in issue was identified with distinguishing the 1st from the 41st authors, both named ‘A. Valiulis’. This caused errors with correctly linking these authors on third party indexing websites. The author names for the 1st and 41st author have been expanded to Arunas Valiulis and Algirdas Valiulis in the author list of this Correction article, in order to circumvent the linking errors. In addition, the presentation of affiliation 1 has been corrected. Affiliation 1 was originally presented as ‘Department of Public Health, Clinic of Children’s Diseases, and Institute of Health Sciences, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania.’ This affiliation is corrected in the affiliation list of this Correction article to ‘Department of Public Health, Institute of Health Sciences, and Clinic of Children’s Diseases, Institute of Clinical Medicine, Vilnius University Faculty of Medicine, Vilnius, Lithuania’.

Published
2020
Full Text
View/download PDF

11. Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases

Author

Tari Haahtela, Jean Bousquet, I Chkhaidze, D. Sergeenko, A. Valiulis, A. Bedbrook, Eugenijus Lesinskas, V. Vilc, L. Dubey, Jonathan Grigg, Joanna Chorostowska-Wynimko, Rusudan Karseladze, U. Suprun, Edvardas Danila, Ioana Agache, Adamos Hadjipanayis, Sergey Sargsyan, R. Savli, N. Khaltaev, O. Katilov, B. Samolinski, Tomas Alasevicius, S. Pietikainen, Algirdas Utkus, Kaja Julge, S. Palkonen, Aurelijus Veryga, S. Cebotari, Mikaela Odemyr, Nils E. Billo, D. Borelli, Violeta Kvedariene, Peter Hellings, B. Sitkauskiene, M. Bewick, L. Vaideliene, J. Banys, Andrew Bush, David Somekh, W. J. Fokkens, Lars Münter, Vilnius University [Vilnius], Institut National de la Santé et de la Recherche Médicale (INSERM), Minister of Health, Minister of Health, Kiev, Minister of Labour, Health and Social Affairs, Minister of Health, Labour and Social Protection, European Parliament, Perugia, European Parliament, Helsinki, Lithuianian Academy of Sciences, Vilnius, Transilvania University of Brasov, Global Alliance Against Chronic Respiratory Diseases (GARD), Imperial College London, Tbilisi State Medical University (Department of Pediatrics), Danylo Halytskiy Lviv National Medical University, VU University Medical Center [Amsterdam], Queen Mary University of London (QMUL), University of Helsinki, University of Tartu, Vinnytsa National Medical University by Mykola Pyrogov, Global Alliance Against Chronic Respiratory Diseases (GARD-WHO), Europeays Diseases Patientn Federation of Allergy and Airwas' Associations (EFA), European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Association of Medical Schools in Europe, State Institute of Phtysiopulmonology by Chiril Draganiuk, European Academy of Paediatrics (EAP/UEMS-SP), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), iQ4U consultants Ltd, National Institute of Tuberculosis and Lung Diseases, European University of Cyprus, Cyprus, Institute of Medical Research [Tbilisi, Georgia], Ilia State University [Tbilisi], Danish Commitee for Health Education, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Yerevan State University, Lithuanian University of Health Sciences [Kaunas, Lithuania], European Health Futures Forum (EHFF), Hospital of Lithuanian University of Health Sciences Kauno Klinikos [Kaunas, Lithuania], University of Amsterdam [Amsterdam] (UvA), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), and Salvy-Córdoba, Nathalie

Subjects
Allergy, IMPACT, Chronic rhinosinusitis, Declaration, Review, Chronic respiratory diseases, DECISION-MAKING, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 0302 clinical medicine, Vilnius Declaration, 11. Sustainability, Immunology and Allergy, 030212 general & internal medicine, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, mHealth, Rhinitis, COPD, CLIMATE-CHANGE, Self-management, 3. Good health, air pollution, asthma, chronic respiratory diseases, guidelines, integrated care pathways, rhinitis, Integrated care pathways, Christian ministry, HEALTH, Life Sciences & Biomedicine, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Immunology, Air pollution, Guidelines, OBSTRUCTIVE PULMONARY-DISEASE, VALIDATION, 03 medical and health sciences, medicine, Intensive care medicine, Asthma, Science & Technology, business.industry, Public health, ALLERGY PROGRAM 2008-2018, RC581-607, medicine.disease, PREVENTION, 030228 respiratory system, 13. Climate action, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Immunologic diseases. Allergy, business
Abstract

Background Over 1 billion people suffer from chronic respiratory diseases such as asthma, COPD, rhinitis and rhinosinusitis. They cause an enormous burden and are considered as major non-communicable diseases. Many patients are still uncontrolled and the cost of inaction is unacceptable. A meeting was held in Vilnius, Lithuania (March 23, 2018) under the patronage of the Ministry of Health and several scientific societies to propose multisectoral care pathways embedding guided self-management, mHealth and air pollution in selected chronic respiratory diseases (rhinitis, chronic rhinosinusitis, asthma and COPD). The meeting resulted in the Vilnius Declaration that was developed by the participants of the EU Summit on chronic respiratory diseases under the leadership of Euforea. Conclusion The Vilnius Declaration represents an important step for the fight against air pollution in chronic respiratory diseases globally and has a clear strategic relevance with regard to the EU Health Strategy as it will bring added value to the existing public health knowledge.

Published
2019
Full Text
View/download PDF

12. Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases

Author

Zuzana Diamant, Stefano Del Giacco, Francesco Branca, Mohamed H. Shamji, Oscar Palomares, Montserat Alvaro-Lozano, Isabel Skypala, Isabella Annesi-Maesano, O. Spranger, Leyla Namazova-Baranova, Cevdet Ozdemir, Frank Ingenrieth, Zlatko Fras, Glennis Scadding, Susanne Lau, Antonio Spanevello, Stefan Vieths, Andreas Bonertz, Arzu Yorgancioglu, Oliver Pfaar, Liam O'Mahony, Tomas Chivato, Peter Schmid-Grendelmeier, Ibon Eguiluz-Gracia, Karin Hoffmann-Sommergruber, Roy Gert van Wijk, Monica Spinola, Carsten B. Schmidt-Weber, Peter Hellings, Domingo Barber Hernández, Mikaela Odemyr, Marek Jutel, María Luisa de Torres, Anke Graessel, Joaquín Sastre, José María Olaguibel, Andrew J. Cant, Andrea Vereda, Philippe Gevaert, Ioana Agache, Sergio Bonini, Antti Lauerma, Internal Medicine, University of Helsinki, Department of Dermatology, Allergology and Venereology, University Management, HUS Inflammation Center, Transylvania University, Brasov, Romania, Department of Epidemiology of Allergic and Respiratory Diseases, Medical School Saint Antoine, IPLESP, INSERM and Sorbonne Université, Paris, France, Federal Agency for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany, Department of Nutrition for Health and Development, Geneva, Switzerland, WHO/HQ, Geneva, Switzerland, University of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom, European Society for Immunodeficiencies, Geneva, Switzerland, Division of Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia, UEMS - Union Europeenne des Medecins Specialistes/European Union of Medical Specialists, Brussels, Belgium, SCOPE Europe, Bruxelles, Belgium, Department of Pediatrics, Russian National Research Medical University of MoH RF, Moscow, Russian Federation, Department of Pediatrics, Central Clinical Hospital of MoSHE (Ministry of Science and High Education), Moscow, Russian Federation, European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), Brussels, Belgium, Dipartimento di Medicina e Chirurgia, Malattie dell'Apparato Respiratorio, Università degli Studi dell'Insubria, Varese – Como, Italy, Dipartimento di Medicina e Riabilitazione Cardio Respiratoria, U.O. di Pneumologia Riabilitativa, Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Tradate, Italy, Department of Pulmonology, Celal Bayar University School of Medicine, Manisa, Turkey, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, Department of Basic Medical Sciences, School of Medicine, Universidad CEU San Pablo, Madrid, Spain, RETIC ARADYAL RD16/0006/0015, Instituto de Salud Carlos III, Madrid, Spain, School of Medicine, University CEU San Pablo, Madrid, Spain, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden, Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic, Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain, ARADyAL Network RD16/0006/0001, Carlos III Health Institute, Madrid, Spain, Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, Department of Otorhinolaryngology-Head and Neck Surgery, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium, Allergy Therapeutics, Worthing, United Kingdom, Bencard Allergie GmbH, Munich, Germany, Department of Otorhinolaryngology-Head and Neck Surgery, UZ Leuven, Leuven, Belgium, Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, Netherlands, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria, Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland, 'ALL-MED' Medical Research Institute, Wroclaw, Poland, Department for Pediatric Pneumology, Immunology and Intensive Care, Charité Universität Medizin, Berlin, Germany, Dermatology and Allergology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, Severe Asthma Unit, Complejo Hospitalario de Navarra, Pamplona, Spain, Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland, Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey, Department of Pediatrics, Division of Pediatric Allergy & Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Department of Allergy, Fundación Jimenez Diaz, Madrid, Spain, Department of Medicine, Instituto Carlos III, CIBERES, Universidad Autónoma de Madrid, Madrid, Spain, RNTNE Hospital, London, United Kingdom, Zentrums Allergie & Umwelt (ZAUM), Technische Universität und Helmholtz Zentrum, München, Germany, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland, Christine-Kühne Center for Allergy Research and Education CK-CARE Davos, Davos, Switzerland, Allergy & Clinical Immunology, Inflammation, Repair and Development, Imperial College, National Heart and Lung Institute, Immunomodulation and Tolerance Group, London, United Kingdom, Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, Imperial College, London, United Kingdom, European Medical Affairs, Sanofi, Milan, Italy, Global Allergy and Asthma Patient Platform, Vienna, Austria, Aimmune Therapeutics, London, United Kingdom, Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy, and Ear, Nose and Throat

Subjects
Big Data, 0301 basic medicine, Clinical immunology, quality criteria, Big data, exposome, environmental health, GUIDELINES, FOOD ALLERGY, Capital Financing, Translational Research, Biomedical, 0302 clinical medicine, White paper, asthma, PRECISION MEDICINE, big data, Immunology and Allergy, 0303 health sciences, implementation science, Health Policy, Disease Management, ASSOCIATION, Public relations, 3. Good health, Europe, OPPORTUNITIES, allergic diseases, translational research, Information Technology, Exposome, BIRTH, Immunology, BIOMARKERS, Bioengineering, Context (language use), Translational research, RM1-950, Asthma care, 03 medical and health sciences, Drug Development, Political science, Hypersensitivity, Humans, DRUG DEVELOPMENT, 030304 developmental biology, business.industry, Research, Information technology, Precision medicine, 030104 developmental biology, 030228 respiratory system, 13. Climate action, 3121 General medicine, internal medicine and other clinical medicine, Therapeutics. Pharmacology, Patient Participation, business, Medical ethics
Abstract

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2019
Full Text
View/download PDF

13. Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma

Author

Robin Gore, Christian Domingo Ribas, Paraskevi Katsaounou, Lorena Garcia Conde, Francesco Menzella, Matthias Gasser, Mario Morais-Almeida, Ismail Kasujee, Michael E. Hyland, Mikaela Odemyr, O. Spranger, and Claus Kroegel

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Severe asthma, MEDLINE, lcsh:Medicine, Disease, 03 medical and health sciences, 0302 clinical medicine, medicine, In patient, 030212 general & internal medicine, Author Correction, Asma, Asthma, business.industry, lcsh:R, Severe persistent asthma, Original Articles, medicine.disease, Disease control, 3. Good health, respiratory tract diseases, 030228 respiratory system, Emergency medicine, Patient survey, business
Abstract

We conducted a large global survey, Still Fighting for Breath, in patients with severe persistent asthma, 10 years after the Fighting for Breath survey to assess the impact of disease on patients' lives and to determine if control and management have changed in recent years. Data were collected from 1333 adults (aged >18 years) and caregivers of children (aged 6–17 years) with severe persistent asthma from nine countries through an online survey conducted in 2016 by GfK. A decade after the first survey, our results showed that the impact of severe asthma has not changed significantly and a high proportion of patients with severe asthma remain inadequately controlled. A large discrepancy was observed between the proportion of patients who perceived their asthma to be well controlled (42%) and the proportion of patients who reported to be well controlled as per the Global Initiative for Asthma (GINA) assessment (6%). Although most patients perceived their asthma to be controlled, many experienced frequent symptoms that affected their daily lives. Thus, there is a need for improved management (support and strategies) of patients with severe persistent asthma and improved coordination of efforts that would enable these patients to achieve better disease control., There is a need for improved management of patients with severe persistent asthma to achieve better disease control http://ow.ly/rv5K30mQdGG

Published
2018

14. Smoking and severe persistent asthma

Author

Michael E. Hyland, Paraskevi Katsaounou, Mikaela Odemyr, Ismail Kasujee, Xavier Jaumont, Μatthias Gasser, O. Spranger, Ioannis Kottakis, Anne Lindberg, and Michael Larbig

Subjects
medicine.medical_specialty, Quality of life, business.industry, Internal medicine, medicine, Severe persistent asthma, Symptom control, business, medicine.disease, humanities, Lung function, respiratory tract diseases, Asthma
Abstract

Smoking has detrimental effects on different clinical aspects of asthma, like accelerated decline in lung function, diminished symptom control, worse quality of life(QoL) and impaired therapeutic r ...

Published
2018
Full Text
View/download PDF

15. Asthma patients are Still Fighting for Breath

Author

Μatthias Gasser, Mikaela Odemyr, Michael E. Hyland, O. Spranger, Ioannis Kottakis, Xavier Jaumont, Ismail Kasujee, and Paraskevi Katsaounou

Subjects
medicine.medical_specialty, Passive smoking, business.industry, Severe asthma, Severe persistent asthma, macromolecular substances, medicine.disease_cause, medicine.disease, Disease control, Poor quality, stomatognathic diseases, Guideline implementation, Treatment compliance, Emergency medicine, Medicine, business, Asthma
Abstract

Fighting for Breath, survey conducted by EFA in 2005, showed that high proportions of patients (pts) were living with uncontrolled severe asthma symptoms, with possible reasons for poor quality of life (QoL) as exposure to passive smoking, lack of treatment by specialist and absence of new treatments. A decade apart in 2016, we conducted Still Fighting for Breath (GfK on behalf of Novartis upon EFA’s invitation), an online survey in 1333 pts with severe persistent asthma (SPA) from 9 countries (Fig1a), aimed to assess impact of SPA on patients’ QoL. Here we compare the impact of severe persistent asthma on patient’s lives between the two surveys. Large discrepancy was seen between the proportion of pts who perceived their asthma to be well-controlled (42%) and the pts who were well-controlled as per GINA assessment (6%). Impact of asthma on psychological well-being and other activities is given in Fig1b. Though steps have been taken to improve the QoL of asthma pts (law banning smoking in public spaces, new treatments), in the last decade the QoL of severe asthmatic pts has not ameliorated significantly (Fig1c). There is a need for improved management (support and strategies) of pts with SPA and better coordination of efforts (enhancing asthma education, assessing perception of control, patient-physician interaction, guideline implementation, treatment compliance, involvement of pts organisations), which would enable these pts to achieve better disease control.

Published
2018
Full Text
View/download PDF

16. Living with severe asthma year 2016

Author

Cristian Domingo Ribas, Mikaela Odemyr, Robin Gore, Ismail Kasujee, Matthias Gasser, Francesco Menzella, Claus Kroegel, Paraskevi Katsaounou, Lorena Garcia Conde, Mario Morais Almeida, and Michael E. Hyland

Subjects
Pediatrics, medicine.medical_specialty, Health professionals, business.industry, Everyday activities, Severe asthma, Severe persistent asthma, Gina guidelines, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Asthma control, medicine, 030212 general & internal medicine, Psychological aspects, Allergists, business
Abstract

Objective: To assess the impact of severe asthma on daily life (asthma control, activity, psychological aspects, treatment). Methods: Data were collected from 1333 adults and children (through caregivers) with severe persistent asthma in 9 countries through an online survey done by GfK on behalf of Novartis in 2016 (Table 1a). Results: Severe asthmatics were diagnosed by respiratory physicians (42%), general practitioners (30%), allergists (21%) and paediatricians (6%). On average, adults were diagnosed 15 years ago, adolescents 7 years and pediatrics 3 years ago. As per patients’ knowledge, 47% were non-allergic. A large discrepancy was seen between real-life control according to GINA guidelines (6%) and self-estimated control (42%). In the previous year, 73% of patients experienced exacerbations that required treatment from a healthcare professional (emergency room, ambulance, physician at home); 34% had ≥2 exacerbations (13%, three; 7%, four; 3%, five; 11%, more than 5). On an average, 20 days of OCS use was reported in the last 6 months. The impact on psychology and activities is shown in Table 1b. Conclusions: Although asthma control is GINA’s main goal, severe asthmatics are uncontrolled with poor quality of life as reflected in their psychological profile and everyday activities. There is a strong disconnect between perceived and actual asthma control. More action is needed to help severe asthmatics achieve control and live normal unrestricted lives.

Published
2017
Full Text
View/download PDF

17. Digital transformation of health and care to sustain Planetary Health: The MASK proof-of-concept for airway diseases—POLLAR symposium under the auspices of Finland’s Presidency of the EU, 2019 and MACVIA-France, Global Alliance against Chronic Respiratory Diseases (GARD, WH0) demonstration project, Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing

Author

Jean Bousquet, Josep M. Anto, Tari Haahtela, Pekka Jousilahti, Marina Erhola, Xavier Basagaña, Wienczyslawa Czarlewski, Mikaëla Odemyr, Susanna Palkonen, Mikael Sofiev, César Velasco, Anna Bedbrook, Rodrigo Delgado, Rostislav Kouznetsov, Mika Mäkelä, Yuliia Palamarchuk, Kimmo Saarinen, Erja Tommila, Erkka Valovirta, Tuula Vasankari, Torsten Zuberbier, Isabella Annesi-Maesano, Samuel Benveniste, Eve Mathieu-Dupas, Jean-Louis Pépin, Robert Picard, Stéphane Zeng, Julia Ayache, Nuria Calves Venturos, Yann Micheli, Ingrid Jullian-Desayes, and Daniel Laune

Subjects
Asthma, Planetary health, mHealth, Finnish Allergy Programme, ARIA, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract In December 2019, a conference entitled “Europe That Protects: Safeguarding Our Planet, Safeguarding Our Health” was held in Helsinki. It was co-organized by the Finnish Institute for Health and Welfare, the Finnish Environment Institute and the European Commission, under the auspices of Finland’s Presidency of the EU. As a side event, a symposium organized as the final POLLAR (Impact of air POLLution on Asthma and Rhinitis) meeting explored the digital transformation of health and care to sustain planetary health in airway diseases. The Finnish Allergy Programme collaborates with MASK (Mobile Airways Sentinel NetworK) and can be considered as a proof-of-concept to impact Planetary Health. The Good Practice of DG Santé (The Directorate-General for Health and Food Safety) on digitally-enabled, patient-centred care pathways is in line with the objectives of the Finnish Allergy Programme. The ARIACARE-Digital network has been deployed in 25 countries. It represents an example of the digital cross-border exchange of real-world data and experience with the aim to improve patient care. The integration of information technology tools for climate, weather, air pollution and aerobiology in mobile Health applications will enable the development of an alert system. Citizens will thus be informed about personal environmental threats, which may also be linked to indicators of Planetary Health and sustainability. The digital transformation of the public health policy was also proposed, following the experience of the Agency for Health Quality and Assessment of Catalonia (AQuAS).

Published
2020
Full Text
View/download PDF

18. Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model

Author

Bernardo Sousa‐Pinto, Luís Filipe Azevedo, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Ludger Klimek, Wienczyslawa Czarlewski, Josep M. Anto, Anna Bedbrook, Violeta Kvedariene, Maria Teresa Ventura, Ignacio J. Ansotegui, Karl‐Christian Bergmann, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Tomás Chivato, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Giulia De Feo, Philippe Devillier, Wytske J. Fokkens, Mina Gaga, Bilun Gemicioğlu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Helga Kraxner, Désirée E. Larenas‐Linnemann, Daniel Laune, Brian Lipworth, Renaud Louis, Michaël Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Mikaëla Odemyr, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, João Almeida Fonseca, Jean Bousquet, and Oliver Pfaar

Subjects
allergic rhinitis, immunotherapy, mobile health, patient‐reported outcomes, real‐life data analysis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real‐life studies. Objective To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK‐air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods We assessed the MASK‐air® data of European users with self‐reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom‐medication score (CSMS). We applied Bayesian mixed‐effects models, with clustering by patient, country and pollen season. Results We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT‐tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT‐tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion In patients with grass pollen allergy, SLIT‐tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally‐harmonised standards for performing and reporting real‐world data in AIT are needed to better understand its ‘real‐world’ effectiveness.

Published
2022
Full Text
View/download PDF

19. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

Author

Jean Bousquet, Oliver Pfaar, Ioana Agache, Anna Bedbrook, Cezmi A Akdis, G. Walter Canonica, Tomas Chivato, Mona Al‐Ahmad, Amir H Abdul Latiff, Ignacio J Ansotegui, Claus Bachert, Abdullah Baharuddin, Karl‐Christian Bergmann, Carsten Bindslev‐Jensen, Leif Bjermer, Matteo Bonini, Sinthia Bosnic‐Anticevich, Isabelle Bosse, Helen A. Brough, Luisa Brussino, Moises A Calderon, Luis Caraballo, Victoria Cardona, Pedro Carreiro‐Martins, Tomas Casale, Lorenzo Cecchi, Alfonso M Cepeda Sarabia, Ekaterine Chkhartishvili, Derek K Chu, Ieva Cirule, Alvaro A Cruz, Wienczyslawa Czarlewski, Stefano delGiacco, Pascal Demoly, Philippe Devillier, Dejan Dokic, Stephen L Durham, Motohiro Ebisawa, Yehia El‐Gamal✝, Regina Emuzyte, Amiran Gamkrelidze, Jean Luc Fauquert, Alessandro Fiocchi, Wytske J Fokkens, Joao A Fonseca, Jean‐François Fontaine, Radoslaw Gawlik, Asli Gelincik, Bilun Gemicioglu, Jose E Gereda, Roy Gerth van Wijk, R Maximiliano Gomez, Maia Gotua, Ineta Grisle, Maria‐Antonieta Guzmán, Tari Haahtela, Susanne Halken, Enrico Heffler, Karin Hoffmann‐Sommergruber, Elham Hossny, Martin Hrubiško, Carla Irani, Juan Carlos Ivancevich, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Omer Kalayci, Musa Khaitov, Ludger Klimek, Edward Knol, Marek L Kowalski, Helga Kraxner, Inger Kull, Piotr Kuna, Violeta Kvedariene, Vicky Kritikos, Antti Lauerma, Susanne Lau, Daniel Laune, Michael Levin, Desiree E Larenas‐Linnemann, Karin C Lodrup Carlsen, Carlo Lombardi, Olga M Lourenço, Bassam Mahboub, Hans‐Jørgen Malling, Patrick Manning, Gailen D Marshall, Erik Melén, Eli O Meltzer, Neven Miculinic, Branislava Milenkovic, Mostafa Moin, Stephen Montefort, Mario Morais‐Almeida, Charlotte G Mortz, Ralph Mösges, Joaquim Mullol, Leyla Namazova Baranova, Hugo Neffen, Kristof Nekam, Marek Niedoszytko, Mikaëla Odemyr, Robyn E O'Hehir, Markus Ollert, Liam O'Mahony, Ken Ohta, Yoshitaka Okamoto, Kimi Okubo, Giovanni B Pajno, Oscar Palomares, Susanna Palkonen, Petr Panzner, Nikolaos GPapadopoulos, Hae‐Sim Park, Giovanni Passalacqua, Vincenzo Patella, Ruby Pawankar, Nhân Pham‐Thi, Davor Plavec, Todor A Popov, Marysia Recto, Frederico S Regateiro, Carmen Riggioni, Graham Roberts, Monica Rodriguez‐Gonzales, Nelson Rosario, Menachem Rottem, Philip W Rouadi, Dermot Ryan, Boleslaw Samolinski, Mario Sanchez‐Borges✝, Faradiba S Serpa, Joaquin Sastre, Glenis K. Scadding, Mohamed H Shamji, Peter Schmid‐Grendelmeier, Holger J Schünemann, Aziz Sheikh, Nicola Scichilone, Juan Carlos Sisul, Mikhail Sofiev, Dirceu Solé, Talant Sooronbaev, Manuel Soto‐Martinez, Manuel Soto‐Quiros, Milan Sova, Jürgen Schwarze, Isabel Skypala, Charlotte Suppli‐Ulrik, Luis Taborda‐Barata, Ana Todo‐Bom, Maria J Torres, Marylin Valentin‐Rostan, Peter‐Valentin Tomazic, Antonio Valero, Sanna Toppila‐Salmi, Ioanna Tsiligianni, Eva Untersmayr, Marilyn Urrutia‐Pereira, Arunas Valiulis, Erkka Valovirta, Olivier Vandenplas, Maria Teresa Ventura, Pakit Vichyanond, Martin Wagenmann, Dana Wallace, Jolanta Walusiak‐Skorupa, De Yun Wang, Susan Waserman, Gary WK Wong, Arzu Yorgancioglu, Osman M Yusuf, Mario Zernotti, Luo Zhang, Mihaela Zidarn, Torsten Zuberbier, and Marek Jutel

Subjects
allergic rhinitis, asthma, immunotherapy, precision medicine, Immunologic diseases. Allergy, RC581-607
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results